China's controversial one-child policy continues to generate controversy and misinformation. This essay challenges several common myths: that Mao Zedong consistently opposed efforts to limit China's population growth; that as a result China's population continued to grow rapidly until after his death, necessitating the switch to mandatory and coercive birth limits; that the launching of the one-child policy in 1980 led to a dramatic decline in China's fertility rate; and that due to the one-child policy, China and the world benefited from 400 million births that were thereby prevented. Evidence is presented contradicting each of these claims: that Mao Zedong at times forcefully advocated strict limits on births and presided over a major switch from voluntary to coercive birth planning after 1970 (not 1980); that as much as 3/4 of the decline in fertility in China since 1970 occurred prior to the launching of the one-child policy; that fertility levels fluctuated and even rose in some years after the one-child policy was launched; and that most of the further decline in Chinese fertility since 1980 can be attributed to economic development, not to coercive enforcement of birth limits.

Chinas controversial one-child policy continues to generate controversy and misinformation. This essay challenges several common myths: that Mao Zedong consistently opposed efforts to limit Chinas population growth; that as a result Chinas population continued to grow rapidly until after his death, necessitating the switch to mandatory and coercive birth limits; that the launching of the one-child policy in 1980 led to a dramatic decline in Chinas fertility rate; and that due to the one-child policy, China and the world benefited from 400 million births that were thereby prevented. Evidence is presented contradicting each of these claims: that Mao Zedong at times forcefully advocated strict limits on births and presided over a major switch from voluntary to coercive birth planning after 1970 (not 1980); that as much as 3/4 of the decline in fertility in China since 1970 occurred prior to the launching of the one-child policy; that fertility levels fluctuated and even rose in some years after the one-child policy was launched; and that most of the further decline in Chinese fertility since 1980 can be attributed to economic development, not to coercive enforcement of birth limits.

This paper empirically examines gender inequality in benefiting from public education, health care and pension transfers over the lifecycle in China. Based on data from the 2010 wave of China Family Panel Studies and government statistics, we apply the internationally comparable method of National Transfer Account to conduct analyses. The results show that, although public health care and pension transfers are remarkably biased against women at old ages, public education transfers are essentially gender-neutral even at the tertiary education level. Gender inequality among older cohorts is largely a legacy of past occupational and earning privileges for males, and the fragmented design of health insurance and pension programs. With growing female advantage in education and a gradual unification of social security system, the gender gap in public transfers in China is expected to narrow in the coming years.

China is in a race between its slowing down economic growth and accelerating population aging. Based on macro data from national accounts and micro data from national household surveys, we apply the National Transfer Account framework to examine recent changes in income and consumption at both the aggregate and individual levels and project the effect of population aging on economic profiles. Our findings show that recent rapid economic growth has resulted in a sizable lifecycle surplus, with labor income far exceeding consumption. With expected increases in consumption, as shown in the historical experience of Taiwan, and with accelerating population aging, however, this surplus is expected to be erased before 2035. China's three-decade long economic boom has led to an age of abundance, but that era will most likely to end in front of the eyes of the current young generation. © 2014 Elsevier B.V. All rights reserved.

Backgrounds

Recent experiments suggest that Citrus bergamia extracts could benefit people with dyslipidemia and obesity but this needs to be further validated.

Methods

A total of 98 people age-matched older adults (65 years) with elevated blood lipids were enrolled to receive 12-week supplementation of a Citrus bergamia extracts-based formulation (CitriCholess)(n = 48) and placebo (n = 50).

Results

No group differences were found in baseline bodyweight, body mass index (BMI), blood cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and glucose levels. CitriCholess supplementation resulted in lower levels than placebo in TG (1.83 ± 0.92 vs. 1.95 ± 1.34 mmol/L, P = 0.612), TC (5.14 ± 0.98 vs. 5.44 ± 0.77 mmol/L, P = 0.097), and LDL-C (3.13 ± 0.74 vs. 3.43 ± 0.62 mmol/L, P = 0.032). Compared to placebo, CitriCholess also resulted in greater reductions in body weight (-0.604 ± 0.939 vs. 0.06 ± 0.74 kg, P < 0.01), waist circumferences (-0.60 ± 1.349 cm vs. -0.16 ± 1.503 cm, P < 0.01) and BMI (-0.207 ± 0.357 vs. 0.025 ± 0.274, P < 0.01). Additionally, females had a significantly higher level of HDL-C than males. TC was significantly correlated with LDL-C, and to a less degree, with TG. TG was inversely correlated with HDL-C. Body weight and waist circumference were negatively correlated with HDL-C and positively correlated with glucose.

Conclusion

12-week supplementation of CitriCholess could benefit lipid metabolism and weight management in old adults with dyslipidemia.

Backgrounds

To study the effects of supplementation of a marine omega-3 poly-unsaturated fatty acids (n3-PUFA) formulation (Omega3Q10) in older adults with hypertension and/or hypercholesterolemia.

Methods

A total of 97 people were enrolled to receive 12-week supplementation of either Omega3Q10 (n = 48) or soybean oil (n = 49). Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and hypertension-related symptoms were determined before and after the supplementation.

Results

There were no baseline differences between the two groups. Omega3Q10 supplementation significantly reduced diastolic blood pressure (DBP) (from 81.6 ± 5.3 mmHg to 79.3 ± 5.2 mmHg, P < 0.05). Blood concentrations of TC and LDL-C decreased significantly and blood HDL-C level increased significantly after 12 weeks of Omega3Q10 (5.5 ± 0.7 vs. 5.3 ± 0.5, P < 0.05; 3.7 ± 0.8 vs. 3.3 ± 0.6, P < 0.05; 1.2 ± 0.6 vs. 1.3 ± 0.5, P < 0.05, respectively) and soybean oil supplementation (5.7 ± 0.8 vs. 5.6 ± 0.7, P < 0.05; 3.6 ± 0.7 vs. 3.4 ± 0.8, P < 0.05; 1.0 ± 0.8 vs. 1.2 ± 0.7, P < 0.05, respectively) but no group differences were found. A significantly greater proportion of the people in the Omega3Q10 group became free from headache and palpitations & chest tightness symptoms after the 12-week supplementation compared to that of the soybean oil group (95.5% vs. 71.4%, P < 0.01; 95.8 vs. 75.5%, P < 0.01, respectively).

Conclusion

12-week supplementation of Fish oil-based PUFA appear to be more effective in improving DBP and hypertension-related symptoms than soybean oil in old adults with hypertension and hypercholesterolemia although both supplementation improved TC, LDL-C and HDL-C concentrations.

Abstract Background With the acceleration of industrialization in low or middle-income nations, the prevalence of respiratory symptoms among older adults is even more significant now in China. Contemporary treatments using Western medicine, such as anti-inflammatory regimens, may be effective in relieving the symptoms, but may have unexpected side effects. Some natural products may be effective in improving respiratory functions, yet their efficacies remain to be examined in randomized, placebo-controlled studies. To evaluate the effects of Lung Support Formula, a nutritional supplement which contains naturally derived Chinese herbal medicines, we conducted a clinical study among older adults in Shanghai, China. Methods A total of 100 patients over 50 years old were recruited and blindly randomized into the treatment or control group. The subjects took either 1 Lung Support Formula capsule or a placebo capsule twice a day for 12 weeks. All subjects were followed-up every 4 weeks to perform investigative and clinical examinations. Repeated measure of analysis of variance was employed to compare the trend of respiratory symptoms scores between the 2 groups during 12 weeks of follow-up. Results Fifty patients from the treatment group and 49 patients in the control group completed the 3-month follow-up. No adverse events were reported in the treatment duration. The percentage of patients reported to have chronic cough, chronic expectoration and chronic bronchitis were significantly decreased in the treatment group when compared with baseline after a 3-month intervention (P < 0.05). The respiratory symptoms scores declined gradually with the lapse of time (P < 0.05) in the treatment group and there were no significant changes in the control group by repeated measure of analysis of variance (P > 0.05). Conclusions The clinical research shows that use of Lung Support Formula shows significant improvements of respiratory symptoms and is well-tolerated in short-term use among older adults. An additional study involving more subjects and longer-term follow-up would be needed to provide convincing evidence of the improvement of respiratory symptoms in the treatment group.